| Literature DB >> 32934830 |
Nolundi Mshweshwe-Pakela1, Bhakti Hansoti2,3, Tonderai Mabuto1,4, Deanna Kerrigan5, Griffiths Kubeka1, Elizabeth Hahn3, Salome Charalambous1,4, Christopher J Hoffmann1,6,7.
Abstract
BACKGROUND: Same-day initiation (SDI) of antiretroviral therapy (ART) has been advocated as an approach to increase linkage to care and overall ART initiation. Clinical trials have demonstrated impressive benefits. However, questions regarding patient preparedness and retention in care remain for routine implementation of this approach.Entities:
Keywords: ARV initiation; HIV testing; SDI; implementation; primary care
Year: 2020 PMID: 32934830 PMCID: PMC7479383 DOI: 10.4102/sajhivmed.v21i1.1085
Source DB: PubMed Journal: South Afr J HIV Med ISSN: 1608-9693 Impact factor: 2.744
Study population characteristics for 826 patients.
| Characteristic | ||
|---|---|---|
| Sites ( | 10 | - |
| - | - | |
| < 29 | 303 | 36.7 |
| 30–39 | 335 | 40.5 |
| ≥ 40 | 188 | 22.8 |
| Male | 298 | 36.1 |
| Female | 528 | 63.9 |
| < 200 | 192 | 23.2 |
| 201–500 | 278 | 33.7 |
| ≥ 501 | 140 | 16.9 |
| Missing | 216 | 26.2 |
Timing of antiretroviral therapy initiation.
| Characteristic | Same-day ( | 1–7 days ( | 8–30 days ( | 31–90 days ( | > 90 days ( | No ART ( | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| % | % | % | % | % | % | ||||||||
| < 29 | 102 | 33.7 | 31 | 10.2 | 106 | 35.0 | 20 | 6.6 | 1 | 0.3 | 43 | 14.2 | 0.009 |
| 30–39 | 89 | 26.6 | 46 | 13.7 | 134 | 40.0 | 16 | 4.8 | 2 | 0.6 | 48 | 14.3 | |
| ≥ 40 | 30 | 16.0 | 28 | 14.9 | 88 | 46.8 | 15 | 8.0 | 2 | 1.1 | 25 | 13.3 | |
| Male | 31 | 10.4 | 49 | 16.4 | 141 | 47.3 | 24 | 8.1 | 2 | 0.7 | 51 | 17.1 | < 0.001 |
| Female | 190 | 36.0 | 56 | 10.6 | 187 | 35.4 | 27 | 5.1 | 3 | 0.6 | 65 | 12.3 | |
| < 200 | 23 | 12.0 | 34 | 17.7 | 105 | 54.7 | 19 | 9.9 | 1 | 0.5 | 10 | 5.2 | < 0.001 |
| 201–500 | 60 | 21.6 | 44 | 15.8 | 131 | 47.1 | 23 | 8.3 | 2 | 0.7 | 18 | 6.5 | |
| > 501 | 42 | 30.0 | 19 | 13.6 | 63 | 45.0 | 6 | 4.3 | 2 | 1.4 | 8 | 5.7 | |
| Missing | 96 | 44.4 | 8 | 3.7 | 29 | 13.4 | 3 | 1.4 | 0 | 0.0 | 80 | 37.0 | |
ART, antiretroviral therapy.
Viral suppression and retention in care at 6 months for those who are on antiretroviral therapy.
| Characteristic | Viral suppression (< 400) at 6 months ( | Retained in care at 6 months ( | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Suppressed | Not suppressed | Retained | Not retained | |||||||
| % | % | % | % | |||||||
| < 29 | 131 | 80.0 | 33 | 20.1 | 0.31 | 171 | 65.8 | 89 | 34.2 | 0.36 |
| 30–39 | 136 | 75.6 | 44 | 24.4 | 189 | 65.8 | 98 | 34.2 | - | |
| ≥ 40 | 92 | 82.9 | 19 | 17.1 | 117 | 71.8 | 46 | 28.2 | - | |
| Male | 123 | 77.4 | 36 | 22.6 | 0.55 | 169 | 68.4 | 78 | 31.6 | 0.61 |
| Female | 236 | 79.7 | 60 | 20.3 | 308 | 66.5 | 155 | 33.5 | - | |
| < 200 | 93 | 75.0 | 31 | 25.0 | 0.16 | 128 | 70.3 | 54 | 29.7 | 0.45 |
| 201–500 | 124 | 81.6 | 28 | 18.4 | 168 | 64.6 | 92 | 35.4 | - | |
| ≥ 501 | 74 | 85.1 | 13 | 14.9 | 93 | 70.4 | 39 | 29.6 | - | |
| No value | 68 | 73.9 | 24 | 26.1 | 88 | 64.7 | 48 | 35.3 | - | |
| Same-day | 118 | 78.1 | 33 | 21.8 | 0.50 | 153 | 69.2 | 68 | 30.8 | 0.47 |
| 1–7 days | 56 | 83.6 | 11 | 16.4 | 76 | 72.4 | 29 | 27.6 | - | |
| 8–30 days | 160 | 79.2 | 42 | 20.8 | 210 | 64.0 | 118 | 36.0 | - | |
| 31–90 days | 23 | 74.2 | 8 | 25.8 | 34 | 66.7 | 17 | 33.3 | - | |
| > 90 days | 2 | 50.0 | 2 | 50.0 | 4 | 80.0 | 1 | 20.0 | - | |
ART, antiretroviral therapy.
Log-binomial logistic regression adjusted for age, gender, CD4 count and antiretroviral therapy initiation group.
| Characteristic | Viral suppression at 6 months | Retention in care at 6 months | ||||
|---|---|---|---|---|---|---|
| Risk ratio | Risk ratio | |||||
| 95% CI | 95% CI | |||||
| < 29 | Ref | - | - | Ref | - | - |
| 30–39 | 0.93 | 0.49–1.78 | 0.84 | 1.19 | 0.78–1.82 | 0.41 |
| ≥ 40 | 1.64 | 0.74–3.61 | 0.22 | 1.50 | 0.90–2.48 | 0.12 |
| Male | Ref | - | - | Ref | - | - |
| Female | 1.46 | 0.80–2.64 | 0.21 | 0.93 | 0.63–1.40 | 0.75 |
| < 200 | Ref | - | - | Ref | - | - |
| 201–500 | 1.58 | 0.85–2.92 | 0.15 | 0.82 | 0.53–1.25 | 0.35 |
| ≥ 501 | 1.90 | 0.88–4.06 | 0.10 | 1.05 | 0.63–1.77 | 0.84 |
| Same-day | Ref | - | - | Ref | - | - |
| 1–7 days | 1.92 | 0.77–4.90 | 0.16 | 0.93 | 0.51–1.71 | 0.82 |
| 8–30 days | 1.34 | 0.67–2.65 | 0.41 | 0.73 | 0.45–1.17 | 0.19 |
| 31–90 days | 1.04 | 0.37–2.96 | 0.93 | 0.79 | 0.38–1.64 | 0.52 |
| > 90 days | 0.26 | 0.03–2.17 | 0.21 | 1.44 | 0.15–13.56 | 0.75 |
ART, antiretroviral therapy.